OpenBench

Executive Summary

OpenBench is a San Francisco-based biotechnology company founded in 2020 that offers a success-driven, AI-enabled platform for small molecule drug discovery. Its core service is structure-based virtual screening, where clients pay only for validated hit series meeting predefined criteria, thereby de-risking and accelerating early-stage discovery for biotech partners. The company operates in the competitive AI drug discovery space, leveraging its platform to reduce upfront costs for partners and align incentives with successful outcomes. While still private with undisclosed funding and valuation, OpenBench's business model positions it to attract partners seeking cost-effective lead generation. The company's niche in success-fee-based screening could differentiate it from peers, though scalability and partner adoption remain key factors to watch.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a major pharmaceutical company50% success
• Q4 2026Completion of Series A funding round to scale platform and expand team60% success
• Q2 2026Publication of validation data demonstrating successful hit discovery for a novel target70% success